

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Craig Adam R</u> _____ (Last) (First) (Middle) 3101 WESTERN AVENUE SUITE 800 _____ (Street) SEATTLE WA 98121 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>CTI BIOPHARMA CORP [ CTIC ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President and CEO		
			3. Date of Earliest Transaction (Month/Day/Year) 11/09/2022					
			4. If Amendment, Date of Original Filed (Month/Day/Year)					
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
common stock	11/09/2022		M		53,996	A	\$0.8411	81,857	D	
common stock	11/09/2022		S <sup>(1)</sup>		46,100	D	\$6	35,757	D	
common stock	11/09/2022		S <sup>(1)</sup>		7,596	D	\$6.01	28,161	D	
common stock	11/09/2022		S <sup>(1)</sup>		300	D	\$6.015	27,861	D	
common stock	11/10/2022		M		188,304	A	\$0.8411	216,165	D	
common stock	11/10/2022		S <sup>(1)</sup>		136,408	D	\$6	79,757	D	
common stock	11/10/2022		S <sup>(1)</sup>		200	D	\$6.005	79,557	D	
common stock	11/10/2022		S <sup>(1)</sup>		26,700	D	\$6.01	52,857	D	
common stock	11/10/2022		S <sup>(1)</sup>		100	D	\$6.015	52,757	D	
common stock	11/10/2022		S <sup>(1)</sup>		16,396	D	\$6.02	36,361	D	
common stock	11/10/2022		S <sup>(1)</sup>		5,800	D	\$6.03	30,561	D	
common stock	11/10/2022		S <sup>(1)</sup>		2,700	D	\$6.04	27,861	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$0.8411	11/09/2022		M			53,996	(2)	05/16/2029	Common Stock	53,996	\$0	859,258	D	
Non-Qualified Stock Option (right to buy)	\$0.8411	11/10/2022		M			188,304	(2)	05/16/2029	Common Stock	188,304	\$0	670,954	D	

**Explanation of Responses:**

- 1. This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- 2. One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Adam R. Craig 11/14/2022  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.